Stazzone Peter 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Sep 4, 2025
Insider Transaction Report
Form 4
Stazzone Peter
Chief Financial Officer
Transactions
- Award
Options to Purchase Common Stock
2025-09-01+50,000→ 50,000 totalExercise: $4.45From: 2025-09-01Exp: 2030-09-01→ Common (50,000 underlying)
Footnotes (1)
- [F1]Effective September 1, 2025, the reporting person was granted stock options to purchase 50,000 shares vesting vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026., subject to continuous service and acceleration upon the occurrence of certain events. The grant was in connection with the reporting person being appointed as the Company's Chief Financial Officer. The exercise price is $4.45 per share.